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Abstract
Background: There are 2.5 million neonatal deaths each year; the majority occur within 48 h of birth, before stabilisation.
Evidence from 11 trials shows that kangaroo mother care (KMC) significantly reduces mortality in stabilised neonates;
however, data on its effect among neonates before stabilisation are lacking. The OMWaNA trial aims to determine the
effect of initiating KMC before stabilisation on mortality within seven days relative to standard care. Secondary objectives
include exploring pathways for the intervention’s effects and assessing incremental costs and cost-effectiveness between
arms.
Methods: We will conduct a four-centre, open-label, individually randomised, superiority trial in Uganda with two parallel
groups: an intervention arm allocated to receive KMC and a control arm receiving standard care. We will enrol 2188
neonates (1094 per arm) for whom the indication for KMC is ‘uncertain’, defined as receiving ≥ 1 therapy (e.g. oxygen).
Admitted singleton, twin and triplet neonates (triplet if demise before admission of ≥ 1 baby) weighing ≥ 700–≤ 2000 g
and aged ≥ 1–< 48 h are eligible. Treatment allocation is random in a 1:1 ratio between groups, stratified by weight and
recruitment site. The primary outcome is mortality within seven days. Secondary outcomes include mortality within 28
days, hypothermia prevalence at 24 h, time from randomisation to stabilisation or death, admission duration, time from
randomisation to exclusive breastmilk feeding, readmission frequency, daily weight gain, infant–caregiver attachment and
women’s wellbeing at 28 days. Primary analyses will be by intention-to-treat. Quantitative and qualitative data will be
integrated in a process evaluation. Cost data will be collected and used in economic modelling.
(Continued on next page)
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Discussion: The OMWaNA trial aims to assess the effectiveness of KMC in reducing mortality among neonates before
stabilisation, a vulnerable population for whom its benefits are uncertain. The trial will improve understanding of
pathways underlying the intervention’s effects and will be among the first to rigorously compare the incremental cost
and cost-effectiveness of KMC relative to standard care. The findings are expected to have broad applicability to hospitals
in sub-Saharan Africa and southern Asia, where three-quarters of global newborn deaths occur, as well as important
policy and programme implications.
Trial registration: ClinicalTrials.gov, NCT02811432. Registered on 23 June 2016.
Keywords: Preterm, Low birthweight, Newborn, Kangaroo care, Skin-to-skin contact, Neonatal mortality, Randomised
controlled trial, Pragmatic
Background
An estimated 2.5 million neonatal deaths occurred in
2018, accounting for nearly half of all deaths in children
aged < 5 years [1]. Within the neonatal period, 36% of
deaths occur on the day of birth and 73% occur in the
first week [2]. Over 80% of neonatal deaths occur in low
birthweight (LBW; weighing < 2500 g) babies, of which
two-thirds are born preterm (≤ 37 weeks gestational age)
[3]. Complications of prematurity are the leading cause
of neonatal and under-5 mortality [1]. Approximately
two-thirds of the 21 million LBW and 15 million pre-
term babies born each year are born in sub-Saharan Af-
rica or southern Asia [4–6]. Together, these two regions
are responsible for 78% of neonatal deaths [1]. With
rates of preterm birth rising or stagnant across the globe
[5, 6], finding ways to improve survival and reduce mor-
bidity in preterm babies is a growing imperative.
Substantial progress could be achieved by improving
facility-based care of small and sick babies in low- and
middle-income countries (LMIC) [7, 8], Estimates suggest
that available interventions could reduce prematurity-
related mortality by 58% [9]. Kangaroo mother care (KMC)
is an intervention consisting of early skin-to-skin contact,
promotion of exclusive breastmilk feeding, early hospital
discharge, and adequate support and close follow-up at
home [10]. The latest Cochrane review (21 trials) and a
meta-analysis (124 studies) demonstrated that KMC among
stable neonates ≤ 2000 g is associated with decreased mor-
tality [11, 12], sepsis [11, 12], hypothermia [11, 12],
hypoglycaemia [12] and length of stay [11] compared to
conventional care. WHO guidelines recommend KMC for
‘routine care of newborns weighing ≤ 2000g… initiated as
soon as newborns are clinically stable’ [13]; however, there
is significant variability in how stability has been defined in
previous randomised controlled trials (RCT) of KMC [14].
The majority of neonatal deaths occur within 48 h of
birth [2], and before stabilisation. The only RCT of KMC
initiated before stabilisation with mortality outcomes was
conducted in Ethiopia, enrolling 123 newborns weighing
< 2000 g [15]. It reported a 43% reduction in mortality;
however, 66% of deaths and the major difference between
arms occurred within 12 h of birth [15, 16]. Further, this
trial excluded > 50% of eligible neonates, did not utilise al-
location concealment and had an apparent group imbal-
ance at baseline (favouring KMC) [15], compromising
robustness. Hence, the effect of initiating KMC before sta-
bilisation remains an unaddressed research priority and a
well-designed RCT, with clear criteria for stability, is war-
ranted to examine mortality impact in non-intensive care
settings [16, 17]. The OMWaNA trial aims to determine
the effect of KMC initiated before stabilisation on mortal-
ity within 7 and 28 days relative to standard care at four
hospitals in Uganda.
There are few published economic evaluations of
KMC, and none conducted rigorously in low-resource
settings from a societal perspective or with systematic
equity assessment. Several studies in LMIC settings have
found that KMC resulted in cost savings for the hospital
or provider [18–21]; however, none has considered
whether KMC may increase costs to households nor
purposely evaluated KMC initiated before stabilisation.
Evidence gaps remain with regards to estimation of the
incremental cost, cost-effectiveness, budget impact and
equity of KMC before stabilisation, particularly consider-
ing the household and societal perspectives. An eco-
nomic evaluation embedded within the trial will
compare the incremental cost and cost-effectiveness of
KMC relative to standard care.
Rigorous studies examining causal pathways for the ef-
fects of KMC on neonatal health outcomes have not
been conducted; thus, scientific understanding is limited.
Potential underlying mechanisms may include improved
thermal control [11, 12], enhanced cardiorespiratory sta-
bility [22, 23], increased breastmilk volume [24, 25],
oxytocin-mediated attenuation of the stress response
[26, 27] and thermally mediated reduction in the risk of
intraventricular haemorrhage (IVH) [28]. The relevance
of these hypothesised causal pathways in neonates for
whom KMC is initiated before stabilisation is unclear,
particularly IVH risk among very low birthweight
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(VLBW; < 1500 g) newborns. Incubators, which are the
standard alternative to KMC, may increase the risk of
nosocomial infections, particularly in newborn units
with ineffective cleaning standards or where incubators
are shared [29, 30]. Thus, further research is warranted
to improve scientific understanding of the physiological
processes underlying the effect of KMC relative to stand-
ard care in this vulnerable population.
Methods/design
This manuscript has been prepared according to the
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) statement (Additional file 1).
Objectives
The primary objective of the OMWaNA trial is to deter-
mine the effect of KMC initiated before stabilisation on
mortality within seven days relative to standard care among
neonates weighing ≤ 2000 g. Secondary objectives include:
1. Determining the effect of KMC initiated before
stabilisation on other important clinical outcomes
relative to standard care among neonates weighing
≤ 2000 g;
2. Estimating the incremental costs and cost-
effectiveness of KMC initiated before stabilisation
relative to standard care from the societal
perspective;
3. Exploring hypothesised causal pathways for the
clinical effects of KMC initiated before stabilisation
relative to standard care among neonates weighing
≤ 2000 g;
4. Examining the barriers and facilitators to initiating
KMC before stabilisation to inform uptake and
sustainability in Uganda.
Study design
This is a four-centre, open-label, individually rando-
mised, superiority trial with two parallel groups: an
intervention arm allocated to receive KMC and a control
arm allocated to receive standard care. Treatment alloca-
tion is random in a 1:1 ratio between groups.
Study setting
The host institution for the trial is the Medical Research
Council/Uganda Virus Research Institute (MRC/UVRI)
and London School of Hygiene & Tropical Medicine
(LSHTM) Uganda Research Unit in Entebbe. The trial is
being undertaken in collaboration with Makerere Uni-
versity and LSHTM. The trial is being conducted at four
Ugandan government hospitals: Entebbe, Jinja and
Masaka Regional Referral Hospitals and Iganga District
Hospital (Fig. 1).
Uganda has a population of 42.9 million and is ranked
162/189 on the Human Development Index (2017) [31].
The population is predominately rural (76%) and the pov-
erty incidence is 27% nationally [32]. Poverty rates vary
considerably, with the highest rates occurring in rural
areas where subsistence farming is the primary source of
income. The Busoga sub-region, where Jinja and Iganga
are located, has the third highest incidence of poverty in
the country (42.1%), while the Wakiso sub-region, where
Entebbe is located, has the second lowest (7.5%) [32].
In Uganda, the neonatal mortality rate is estimated at
19.9 per 1000 live births, with a resultant 32,296 deaths
in 2018 [1]. Complications of prematurity are respon-
sible for 27% of neonatal deaths [33], as compared to
35% globally [1]. An estimated 107,921 (7%) Ugandan
babies were born preterm in 2014 [5].
Characteristics of the four trial hospitals are shown in
Table 1. Each hospital has a neonatal special care unit,
which accepts referrals from their respective region/dis-
trict. The level of equipment in these government facil-
ities differs, but all have: bag-mask resuscitation;
incubators and/or overhead radiant heaters for thermal
support; intravenous (IV) fluids, nasogastric tubes and
syringes for feeding support; oxygen supply (concentra-
tors or cylinders) and nasal prongs for respiratory sup-
port; IV and oral antibiotics; phototherapy for jaundice;
aminophylline for prematurity-associated apnoea; and
phenobarbital for seizures. Pulse oximetry and impro-
vised bubble continuous positive airway pressure (CPAP)
ventilation are available at some of the trial hospitals. In-
vasive ventilation and surfactant are unavailable at all
sites. Standard care at the four sites involves provision of
intermittent KMC to neonates weighing ≤ 2000 g once
stable, in line with current WHO guidelines.
Study population
The trial will include admitted neonates weighing ≤
2000 g for whom the indication for KMC is ‘uncertain’
according to WHO guidelines concerning clinical stabil-
ity [10]. Eligibility criteria are listed below.
Inclusion criteria:
 Neonate admitted to trial hospital (inborn or
outborn);
 Singleton, twin or triplet (if triplet pregnancy
resulted in demise or stillbirth of ≥ 1 fetus);
 Birthweight ≥ 700 g and ≤ 2000 g;
 Chronological age ≥ 1 h and < 48 h at time of
screening;
 Alive at time of recruitment;
 Parent/caregiver able and willing to provide KMC;
 Parent/caregiver willing to attend follow-up visit;
 Indication for KMC ‘uncertain’ according to WHO
guideline concerning clinical stability: pragmatically
defined as receiving ≥ 1 therapy: oxygen; CPAP; IV
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fluids; therapeutic antibiotics (for suspected or
confirmed infection); phenobarbital.
Exclusion criteria:
 Result of triplet or higher-order multifetal pregnancy
(unless triplet pregnancy resulted in demise or still-
birth of ≥ 1 fetus);
 Indication for KMC ‘certain’ according to WHO
guidelines: pragmatically defined as clinically well
neonates receiving none of the above therapy-based
criteria;
 Severely life-threatening instability defined as oxygen
saturation (SpO2) < 88% in oxygen and ≥ 1 of:
– Respiratory rate < 20 or > 100 breaths/min;
– Apnoea requiring bag-mask ventilation;
– Heart rate (HR) < 100 or > 200 beats/min;
 Severe jaundice requiring immediate management;
 Active neonatal seizures;
 Major congenital malformation;
 Parent does not provide written informed consent to
participate in trial.
Study procedures
The schedule of procedures for the OMWaNA trial is
outlined in Fig. 2.
Figure 3 describes the flow of participants from the
time of screening through follow-up at 28–30 days.
Screening
All admitted neonates weighing ≤ 2000 g at the four trial
hospitals will be screened for eligibility by a study nurse
or medical officer (Fig. 3a, ‘Screening for eligibility’). Eli-
gibility will be assessed as soon as possible after admis-
sion and once the baby is aged ≥ 1 h to allow for
transition immediately after birth. This is in recognition
of the large physiological changes that take place follow-
ing delivery and that the stability of a newborn aged < 1
h may change rapidly and not accurately reflect their
subsequent clinical trajectory. Trained study staff will as-
certain chronological age and relevant pregnancy details
by examining source documents and/or conducting a
standardised maternal interview. Weight will be mea-
sured using the Seca™ 384 electronic weighing scale. A
focused examination will be conducted to assess for the
presence of major congenital malformations, severe
jaundice and seizures.
Neonates for whom KMC is indicated per WHO guide-
lines (i.e. are considered ‘stable’) will be excluded and re-
ceive KMC as part of standard care (Fig. 3a, ‘Stable to
receive KMC’). Neonates for whom the indication for
Fig. 1 Map of Uganda showing location of the four OMWaNA trial hospitals. Source of map data: Google Maps©, 2019
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KMC is ‘uncertain’ per WHO guidelines (i.e. are ‘prior to
stability’) will be further assessed. For those neonates who
are found to meet eligibility criteria (Fig. 3a, ‘Screening for
eligibility’), a trained member of the study staff will moni-
tor HR and SpO2 using a Masimo Rad-8© pulse oximeter
for 10min and measure respiratory rate manually by
counting breaths for 1 min. Those found to meet the cri-
teria for ‘life-threatening instability’ (Fig. 3a, ‘Too un-
stable’), or who have seizures or jaundice requiring
treatment, will not be eligible for immediate recruitment
and will enter a cycle of reassessment every 3 h. All will
continue to receive clinically indicated treatments and car-
diorespiratory monitoring at the discretion of the on-duty
paediatrician, medical officer or nurse. If, during any re-
assessment within the first 48 h, a neonate is found to
have improved and no longer meets exclusion criteria, re-
cruitment may proceed. Neonates who continue to have
life-threatening instability or meet other exclusion criteria
by 48 h will be permanently excluded.
Informed consent
Written informed consent will be sought from the par-
ents of all participants for the following: neonatal
inclusion in the study; collection of sociodemographic
and clinical data; and randomisation to a study arm.
Consent will also be obtained for the possibility that the
caregiver will provide continuous skin-to-skin contact, if
randomised to that arm. Additionally, consent will be
obtained for the collection of household socioeconomic
and cost data, as well as data on infant–caregiver attach-
ment and women’s wellbeing. Study medical officers or
nurses will request informed consent. The preferred per-
son to provide informed consent for neonatal involve-
ment is the mother. If a mother is unavailable or too ill
to provide consent, consent can be obtained from the
father. Once the mother is available and feeling well
enough, the informed consent process will be repeated
to confirm her consent for her baby’s continued partici-
pation. An impartial and literate witness will be used
during consent for non-literate parents, as per Inter-
national Council for Harmonisation-Good Clinical Prac-
tice (GCP) guidance.
Collection of baseline data
Study staff will be trained in infection prevention and
standard operating procedures (SOP) will detail infection
Table 1 Characteristics of Ugandan trial hospitals, with resource availability in February 2019
Entebbe Hospital Iganga Hospital Jinja Hospital Masaka Hospital
Facility level of care Regional District Regional Regional
Catchment area [32] Semi-urban 86% rural 86% rural 65% rural
Local poverty incidence (%) [32] 7.5 42.1 42.1 24.3
Live births (2018) 5706 6894 5287 9588
Neonatal admissions (2018) 597 933 698 2016
Born at an outside facility (n (%)) 12 (2) 32 (3) 98 (14) 504 (25)
Birthweight < 2500 g (n (%)) 248 (42) 421 (45) 234 (34) NAa
Birthweight < 1500 g (n (%)) 229 (38) 114 (12) 115 (17) NAa
Average length of stay (days) 21 3–4 7 4
Paediatrician 1 1 3 2
Nurses in neonatal unit 8b 5 9 6
Overhead radiant heater 3 functional 1 functional 4 functional 2 functional
Incubator 2 functional 4 functional 3 functional, 6
non-functional
3 functional
Open cots 0 7 10 8
Oxygen supply 2 concentrators,
2 cylinders
1 concentrator,
1 cylinder
4 concentrators,
3 cylinders
2 non-functional
concentrators, 1 cylinder
Bubble CPAP (improvised) 1 1 1 0
Pulse oximeter 0 1 4 1
Phototherapy 2 functional 1 functional, 1 non-functional 3 functional 4 functional
KMC beds, chairs 4 beds (KMC room),
no chairs
5 beds (3 KMC room, 2
postnatal corner), no chairs
4 beds (KMC room),
20 chairs (neonatal unit)
4 beds (KMC room),
no chairs
CPAP continuous positive airway pressure, KMC kangaroo mother care, NA not applicable
a Neonatal admissions data were not available for Masaka Hospital
b The neonatal unit at Entebbe Hospital has six government-employed nurses and two volunteer nurses
Medvedev et al. Trials          (2020) 21:126 Page 5 of 19
control measures for the use of study equipment to avoid
contamination between participants. Axillary temperature
will be measured with a digital thermometer in degrees
Celsius; three measurements will be taken to enable calcu-
lation of the mean value. Respiratory rate will be measured
manually by counting breaths for 1 min. Blood glucose
will be measured with a capillary sample using the study
glucometer. Head circumference (HC) will be measured
and a physical examination will be conducted. Baseline
clinical and anthropometric data will be collected as soon
Fig. 2 OMWaNA trial schedule of enrolment, interventions and assessments 1. The start of trial procedures (time 0) is defined as when the pulse
oximeter is attached for cardio-respiratory monitoring 2. All participants are reviewed daily while admitted to the hospital 3. All participants
receive continuous monitoring of heart rate (HR) and oxygen saturation (SpO2) for 72 h after randomisation. Continuous monitoring continues
until participants no longer require any form of respiratory support 4. HR, SpO2, axillary temperature and respiratory rate are measured every 6 h
until stability criteria are met, after which the frequency transitions to daily 5. Blood glucose is measured daily and may be discontinued once the
participant tolerates full enteral feeds 6. Participants are weighed on day 5, then daily until discharge (unless deemed too unstable by site study
staff) 7. Socioeconomic data, including household details, are collected within 48 h of enrolment. During this time, study staff also inform families
that they will be asked about their household expenditures and activities over the coming month 8. For participants at Entebbe and Jinja
Hospitals, cranial ultrasounds are performed on days 1, 3 and 7 of hospitalisation (or as an outpatient if discharged before day 7) and on follow-
up at day 28–30 9. The Women’s Capabilities Index (WCI) is administered to all mothers within 48 h of enrolment and on days 28–30 to assess
women’s wellbeing 10. The Maternal Infant Responsiveness Instrument (MIRI) is administered on days 28–30 to assess infant-caregiver attachment
11. Duration of admission is measured as the mean time (days and hours) from hospital admission to discharge
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Fig. 3 (See legend on next page.)
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as possible after enrolment, with the exception of gesta-
tional age and crown-foot length, which may be delayed
to within 48 h of enrolment. Gestational age will be esti-
mated using Ballard score [34], last menstrual period and
foot length [35]. Length will be measured using the Seca™
210 neonatal measuring mat.
Socioeconomic data, including household details,
will be collected within 48 h of enrolment using stan-
dardised parent interviews. The Women’s Capabilities
Index (WCI) questionnaire will also be administered
to mothers during this timeframe. Study staff will also
inform families that, over the coming month, they
will be asked about their expenditures and the activ-
ities of members of their household in order to evalu-
ate the economic impact of KMC relative to standard
care.
Randomisation, allocation and blinding
Treatment allocation is random in a 1:1 ratio between
groups using permuted blocks of varying block sizes. The
allocation sequence was computer-generated centrally at
MRC/UVRI by an independent statistician, stratified by
birthweight (< 1000, 1000–1499 or ≥ 1500 g) and recruit-
ment site. The random allocation sequence is uploaded
onto the REDCap (Research Electronic Data Capture,
Nashville, TN, USA) platform [36] and accessed using a
computer with Internet access at each site. The random-
isation server and research database are hosted at the
MRC/UVRI and LSHTM Unit data centre. This precludes
any possibility of study staff viewing the allocation se-
quence. Allocation is revealed only after the study medical
officer or nurse has entered all required screening data
into REDCap. The mother is the unit of randomisation;
twin and triplet participants will be allocated to the same
arm. Each site has one spare computer in case of break-
down or theft; if both fail, the site will revert to random al-
location using telephone as the back-up option. Given the
nature of the KMC intervention, blinding parents/care-
givers is not possible. Process and outcome data will be
anonymised and all analyses will be blinded. Analyses will
be unblinded for the Data and Safety Monitoring Board
(DSMB) at their request.
Intervention arm
Neonates in the intervention group will receive KMC
initiated as soon as possible after randomisation.
Neonates will be naked except for hat and diaper, and
will be secured to the exposed chest of the caregiver
using a KMC wrap (Fig. 4a). The caregiver is seated or
lying on a bed, while the neonate receives any clinically
indicated therapies (e.g. IV fluids, antibiotics, oxygen).
Caregivers will be encouraged to provide KMC as close
to continuously as possible, aiming for at least 18 h per
day. If the primary caregiver is unavailable, another fam-
ily member (e.g. father, grandmother) or close friend
(helper) will be encouraged to provide KMC. If a family
member or helper is not available to continue KMC, the
neonate will be placed into an incubator or under a radi-
ant heater until the caregiver returns. KMC will con-
tinue to be encouraged until discharge and at home after
discharge, as per WHO guidelines. KMC is commonly
practiced until the baby is 2500 g or resists the KMC
position, which is often at 4–10 weeks after birth.
Neonates who meet any of the criteria for stopping
KMC (Fig. 3d, ‘Criteria for stopping KMC’) will be tem-
porarily withdrawn from the intervention and cared for
in an overhead heater or incubator at the discretion of
the on-duty paediatrician. KMC may be restarted once
all of the following criteria are met: (1) no longer meet
any of the stopping criteria; (2) no apnoea requiring bag-
mask ventilation for 24 h; (3) not on phototherapy; (4)
no seizures for 24 h; (5) no abdominal distension; (6)
caregiver available and willing to do KMC; (7) no health-
care worker concerns about clinical condition.
Control arm
Neonates in the control group will be cared for in an in-
cubator (Fig. 4b) or under a radiant heater. Caregivers
are able to touch, hold and feed their baby, but may not
provide any skin-to-skin contact until the neonate meets
WHO criteria for KMC, i.e. are considered ‘stable’. Neo-
nates will be considered stable when the following cri-
teria have been met for a continuous period of ≥ 24 h:
(1) breathing spontaneously with SpO2 > 90% in room
air; (2) no need for supplemental oxygen or CPAP; (3)
respiratory rate 40–< 60 breaths/min; (4) no apnoea; (5)
HR 80–< 180 beats/min; (6) axillary temperature 36.0–
37.4 °C; and (7) no need for IV fluids. These criteria are
consistent with those being used in the WHO-led Im-
mediate KMC (I-KMC) trial [37]. Once stable, neo-
nates can transition to routine (intermittent) KMC
with the caregiver in line with standard care at the
(See figure on previous page.)
Fig. 3 Overview of trial flow including routine procedures and key criteria for eligibility screening, assessing severe illness and stopping KMC 1.
Refusal to feed, feed intolerance or abdominal distension (after starting feeds) 2. Increased respiratory support defined as new oxygen or CPAP
requirement 3. Axillary temperature < 35.5°C after 1 h of observed skin-to-skin contact, not associated with environment or with hypoglycaemia 4.
For participants at EH and JH, cranial ultrasounds will be performed on days 1, 3 and 7 of hospitalisation (or as an outpatient if discharged before
day 7) and on follow-up at days 28–30. CPAP continuous positive airway pressure, EH Entebbe Hospital, HC head circumference, JH Jinja Hospital.
a Screening for eligibility. b Signs of severe illness. c Suspected infection criteria. d Criteria for stopping KMC
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trial sites. As in the intervention arm, neonates in the
control arm who meet any of the criteria for stopping
KMC (Fig. 3d, ‘Criteria for stopping KMC) will be
cared for in an overhead heater or incubator until re-
start criteria are met.
Participant flow around study sites
Participant flow around the study sites is illustrated in
Fig. 5, using Entebbe Hospital as an example. All neo-
nates are initially stabilised and assessed at a radiant
heater. While clinically ‘unstable’, neonates allocated to
KMC are cared for in a study bed and those allocated to
standard care are cared for in an incubator or radiant
heater. Participants in both arms are transferred to the
KMC step-down unit once they meet stability criteria.
Neonatal care capacity building
Substantial expansion of neonatal care capacity and
infrastructure at all trial sites has been embedded
within the OMWaNA trial. This includes enlargement
of the KMC areas within the neonatal units to ensure
Fig. 4 OMWaNA intervention (KMC) and control (standard incubator care) arms. Images: University of California San Francisco Preterm Birth
Initiative, with caregiver consent for publication (a); Melissa Medvedev (b)
Fig. 5 Study site participant flow for the OMWaNA trial. Inc incubator, RH radiant heater
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that all neonates, whether in KMC or not, can be
cared for safely. Additional infrastructure improve-
ments include sinks to provide an optimal environ-
ment for infection control, bathrooms/toilets for
mothers/caregivers and office space for clinical staff.
One study medical officer and 4–5 study nurses have
been recruited to join the clinical teams at each site.
Further, each site will be provided with the following
supplies and equipment: six Masimo Rad-8© oxi-
meters with neonatal sensors; one oxygen concentra-
tor; two thermometers; one glucometer with blood
glucose testing strips; one neonatal ventilation bag
and mask; one Seca™ 384 neonatal weighing scale;
one Seca™ 210 neonatal measuring mat; 2–3 paediat-
ric stethoscopes; and a minimum of four adjustable
beds. In addition, KMC wraps will be provided to
support practice in each unit.
Clinical care for neonates in both arms
Clinical monitoring
All participants will be evaluated at least once by a study
paediatrician or medical officer during the first 24 h after
randomisation. All participants will receive continuous
monitoring and recording of HR and SpO2 for 72 h after
randomisation. Continuous monitoring will continue
until participants no longer require any form of respira-
tory support. HR, SpO2, axillary temperature and re-
spiratory rate will be measured and recorded by a study
nurse every 6 h until stability criteria are met, after
which the frequency will transition to daily. According
to the same frequency, a study nurse will observe and
record the presence or absence of clinical signs of re-
spiratory distress, including chest in-drawing, nasal flar-
ing and grunting. Blood glucose will be measured every
6 h during the first 24 h after randomisation unless it is
< 2.6 mmol/L, in which case it will be measured hourly
until two or more consecutive readings are in normal
range (2.6–6.9 mmol/L). Subsequently, blood glucose
will be measured daily until a participant is tolerating
full enteral feeds.
Medical therapies
All enrolled neonates will receive clinically indicated
treatments, including but not limited to oxygen, IV
fluids (given by bolus or burette), antibiotics, aminophyl-
line, anticonvulsant medicines and phototherapy. Stan-
dardised clinical guidelines will be followed for common
neonatal conditions, including preterm fluids/feeding
(including breastfeeding), suspected and proven sepsis,
respiratory distress, jaundice and seizures. Bubble CPAP
will be provided at the discretion of the on-duty paedia-
trician at sites where this is the standard of care. Jaun-
dice will be treated with phototherapy for neonates in
both arms. All caregivers will be trained in KMC regard-
less of study arm.
Clinical deterioration
Neonatal unit staff at all sites will be trained to recognise
signs of severe illness (Fig. 3b, ‘Signs of severe illness)
and to inform study staff if a participant meets any of
these criteria. The study paediatrician or medical officer
(or study nurse if neither is present) will examine the
neonate as soon as possible to assess whether signs of
early-onset (< 72 h of age) or late-onset (≥ 72 h of age)
infection (Fig. 3c, ‘Suspected infection criteria’) are
present. Neonates will be reassessed for signs of severe
illness and infection during daily rounds. Where avail-
able, a blood culture will be obtained as soon as possible
if a neonate meets criteria for suspected infection; how-
ever, this will not delay administration of antibiotic ther-
apy. Study staff will also assess if the neonate meets
criteria for temporary withdrawal from KMC (Fig. 3d,
‘Criteria for stopping KMC’). At the discretion of the
study paediatrician, neonates may be referred to a
higher-level facility for more specialised care; however,
existing data indicate that this is an uncommon
occurrence.
Discharge and follow-up
At the time of discharge, all caregivers will be provided
with an illustrated handout on neonatal danger signs
and instructed to contact the site study team or seek
medical help if their baby becomes unwell. Caregivers of
babies in both arms will be encouraged to continue
KMC at home. All participants will be given an appoint-
ment to attend the follow-up clinic at the respective
study site on days 28–30. At this visit, cranial ultrasound
(Entebbe and Jinja Hospitals only) and anthropometry
will be performed, feeding practices and outcomes (alive,
dead, readmitted) will be documented, and the WCI and
Maternal Infant Responsiveness Instrument (MIRI)
questionnaires will be administered to mothers.
If participants are discharged before day 7, additional
follow-up will be arranged according to study site. If par-
ticipants do not attend the follow-up visit, a telephone
call will be made the same day to ascertain outcome and
feeding practices and to arrange follow-up, either in the
clinic or at the families’ home, as soon as possible. Rou-
tine follow-up beyond the planned study follow-ups will
be provided by the study staff according to standard
practice and based upon the clinical need of the baby.
Safety reporting and study monitoring
Adverse events (AE) are medical events or laboratory
findings, which result in a change in clinical manage-
ment after randomisation and until 28 days after birth. A
serious adverse event (SAE) is defined as an event that
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results in death, is life-threatening, requires hospitalisa-
tion or prolongation of hospitalisation, results in persist-
ent or significant disability, or requires intervention to
prevent permanent impairment or damage [38]. Study
medical officers and nurses will inform the site paediatri-
cian about any SAE occurrence within 24 h. SAEs will
be followed up by the paediatrician until their resolution
or stabilisation, or until causality is determined to be un-
related to the trial intervention. If a serious but unex-
pected AE occurs, which might be related to the trial
intervention, a SAE report will be submitted to the Re-
search Ethics Committees (REC) at UVRI and LSHTM
within 48 h of the investigators becoming aware of the
event, with a follow-up report provided within a further
five working days. This expedited reporting will be lim-
ited to those outcomes not already listed as primary or
secondary outcomes, yet which might reasonably occur
as a consequence of the trial intervention. All SAEs will
be reported to the Sponsor and RECs as part of their re-
spective annual progress and safety report.
The DSMB will oversee the overall integrity of the
study, its safety and its continued relevance and ability
to answer the primary objective. DSMB members in-
clude a perinatal epidemiologist/statistician (chair), a
South African neonatologist and a neonatal bioethicist.
The DSMB will receive a summary of SAEs after one
month of recruitment, then move to every three or six
months; the DSMB will decide the frequency following
the first report. An interim analysis will be performed on
the primary outcome when approximately half of neo-
nates have been randomised. An independent statistician
will perform the interim analysis, blinded to treatment
allocation and report to the DSMB. Analyses will be un-
blinded at the request of the DSMB. In light of these
data and other evidence from relevant studies, the
DSMB will inform the Trial Steering Committee (TSC)
if in their view: it is evident that no clear outcome will
be obtained with the current trial design; they have a
major ethical or safety concern; or it is evident that the
intervention is clearly superior and continuing the trial
would be unethical to those in the control arm. The
TSC will make the final decision on study continuation.
The study will be monitored by the Reciprocal Moni-
toring Scheme of the East African Consortium for Clin-
ical Research in collaboration with the Research
Compliance and Quality Assurance section of the MRC/
UVRI and LSHTM Unit. Dedicated study monitors, in-
dependent of the study team, will oversee progress and
ensure the trial is conducted and data are handled in ac-
cordance with the protocol, SOPs and applicable ethical
and regulatory requirements. In addition, the UVRI REC
will conduct initial site visits with neonatal specialists
from the Uganda Paediatrics Association and the Ugan-
dan Ministry of Health Newborn Steering Committee.
The trial may be subject to audit by LSHTM under their
remit as Sponsor, the Study Coordination Centre and
other regulatory bodies to ensure adherence to GCP.
Outcome measures
The primary outcome is all-cause early neonatal mortality
(within seven days). Estimates suggest that three-quarters
of neonatal deaths occur in the first week of life [2].
Secondary outcomes are as listed below.
1. Prevalence of hypothermia (axillary temperature <
36.5 °C) at 24 h after randomisation
Axillary temperature will be assessed using a digital
thermometer.
2. Time from randomisation to clinical stabilisation
(days and hours)
The date and time of randomisation and clinical
stabilisation will be prospectively recorded. Stability
is defined as having met all of the following criteria
for a continuous period of at least 24 h:
 Breathing spontaneously with SpO2 > 90% in
room air;
 No need for supplemental oxygen or CPAP;
 Respiratory rate 40– < 60 breaths/min;
 No apnoea;
 HR 80– < 180 beats/min;
 Axillary temperature 36.0–37.4 °C;
 No need for IV fluids.
3. Time from randomisation to death (days and hours)
The date and time of death will be prospectively
recorded from the death certificate for in-hospital
deaths. For deaths occurring after discharge, the
date will be recorded according to verbal report by
the parent/caregiver.
4. Time from randomisation to exclusive breastmilk
feeding (days and hours)
The date and time of randomisation and initiation
of exclusive breastmilk feeding will be prospectively
recorded. Exclusive breastmilk feeding is defined as
receiving breastmilk, either directly from the breast
or by nasogastric tube, bottle, cup or spoon after
expression from the breast, as the sole source of
nutrition [39].
5. Mean duration of hospital admission (days and
hours)
The date and time of admission and discharge will
be documented prospectively for the first admission
episode.
6. All-cause mortality within 28 days
This outcome will be documented at the follow-up
visit on days 28–30. If participants do not attend, a
telephone call will be made the same day to
ascertain outcome.
7. Mean frequency of readmission at 28 days
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Episodes in which a neonate who had been
discharged from a hospital is readmitted to the
same hospital during the first 28 days will be
prospectively recorded. Episodes in which a neonate
is readmitted to a different hospital will be recorded
according to verbal report by the parent/caregiver
on follow-up at days 28–30.
8. Mean daily weight gain (g/day) at 28 days
Mean daily weight gain will be calculated as the
difference between weight at enrolment and on
follow-up at days 28–30, as measured by the study
scale.
9. Women’s wellbeing at 28 days
Women’s wellbeing will be assessed using the WCI,
a capability-based composite measure of quality of
life that will capture the broader effects to the
mother of practicing KMC. The WCI includes six
domains (physical strength, inner wellbeing,
household wellbeing, community relations,
economic security, happiness), with a total of 26
sub-dimensions [40]. Developed and validated in
Malawi, the WCI was recently adapted for use in
Uganda [41].
10. Infant–caregiver attachment at 28 days
Infant–caregiver attachment will be assessed using
the MIRI, a 22-item questionnaire that measures
maternal recognition of responsiveness to infant
cues, maternal recognition of infant responsiveness
and difficulties in responsiveness [42]. The MIRI
was developed and validated in the United States,
and is now being used in Uganda [43].
Process outcomes
Understanding the hypothesised causal pathways for
clinical effects of the intervention (objective 3) will be
achieved by measurement of the following process out-
comes, which are categorised as providing very early
(within 24 h), early (within 72 h) or late clinical impact.
1. Cardiorespiratory stability within 24 h, 72 h after
randomisation
Proportion of time spent with suboptimal HR (<
100 bpm) and SpO2 (< 85%) over the first 24 h and
72 h after randomisation, measured and recorded
continuously using the study pulse oximeter.
2. Prevalence of hypothermia (axillary temperature <
36.5 °C) at 24 h, 72 h after randomisation
Axillary temperature will be assessed using a digital
thermometer.
3. Hypothermia density within 24 h, 72 h after
randomisation
Hypothermia density is defined as the proportion of
time the axillary temperature is < 36.5 °C during a
defined time period. Axillary temperature will be
measured every 6 h during the first 24 h after
randomisation and until clinically stable, after
which it is measured daily.
4. Prevalence of hypoglycaemia (blood glucose < 2.6
mmol/L) within 24 h, 72 h after randomisation
Blood glucose will be measured using a study
glucometer and glucose testing strips.
5. Presence and severity of IVH at 72 h, seven days
after randomisation; presence of late intracerebral
sequelae of prematurity at days 28–30
IVH is a complication of prematurity characterised
by bleeding within the cerebral ventricles, typically
originating from the periventricular germinal
matrix; severity ranges from grade 1 (mild) to grade
4 (severe) [44]. Late intracerebral sequelae include
cystic degeneration, post-haemorrhagic hydrocephalus
and cerebral atrophy. The study paediatrician or
medical officer at two of the four hospitals (Entebbe
and Jinja) will perform cranial ultrasounds using a
Sonosite Edge II© portable ultrasound machine. Both
standard and linear probes will be used to assess for
abnormalities according to a defined protocol and will
include ≥ 11 coronal and sagittal views. Images will be
read by an independent expert.
Data collection, management and security
Trial data will be electronically entered into trial-specific
case report forms on tablets using an offline, mobile
REDCap application, with inbuilt ranges and consistency
checks. Data from tablets will be synchronised once daily
over a secure connection with the web-based REDCap
database, hosted at the MRC/UVRI and LSHTM Unit
data centre. Cardiorespiratory data from Masimo Rad-
8© oximeters will be downloaded using Stowood Visi-
Download™ software, captured in CSV files, securely
transmitted to MRC/UVRI, analysed with PROFOX™
software and reconciled with the trial database. Cranial
ultrasound images will be stored in OsiriX Dicom™ soft-
ware and interpreted blind to allocation and clinical de-
tails. Logs linking parent/caregiver names and residence
location will be stored separately on password-protected
computers, with a hard copy stored in locked cabinets in
secure rooms at all sites.
All data will be stored in institutional servers at the
MRC/UVRI and LSHTM Unit during the study. Data
from the web-based REDCap database will be down-
loaded and stored on institutional servers at LSHTM in
London for access by the PIs and independent statisti-
cian for analysis and preparation of reports for the
DSMB, respectively. These secure, password-protected
servers are only accessible within the LSHTM network
and activity is fully audited, recording both login details
and file system access. Access will be limited to essential
research personnel.
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Sample size
Assuming a control mortality rate of 25% across the four
recruitment sites, 1750 neonates (875 per arm) would
enable us to detect a relative difference between arms of
22.4% (5.6% absolute difference) with 80% power and a
significance level of 5%. If the control mortality rate
were in fact as low as 18%, we would still be able to de-
tect a relative difference of 27% (absolute difference of
4.8%). We plan to recruit 2188 neonates (1094 per arm)
in order to allow for 10% withdrawal due to clinical de-
teriorations and consent withdrawal, and 10% dilution
due to non-compliance and loss to follow-up. This sam-
ple size would enable us to detect absolute reductions of
6.3% and 5.4% from control rates of 25% and 18%, re-
spectively, with 90% power.
Statistical analyses
Summary of baseline data and flow of patients
Baseline characteristics of enrolled neonates will be sum-
marised by treatment arm. Descriptive statistics for con-
tinuous variables will include mean, standard deviation,
median, range and number of observations. Categorical
variables will be summarised as counts and proportions.
Participant flow through screening, randomisation, alloca-
tion and follow-up will be illustrated in a CONSORT dia-
gram (Fig. 6), with reasons for exclusion, non-adherence,
loss to follow-up and non-analysis documented.
Primary and secondary outcome analyses
Primary and secondary outcome analyses will be carried
out on all neonates as randomised (‘intention-to-treat’).
The rate of loss to follow-up will be reported. We will re-
port risk ratios for mortality within seven days (primary
outcome) and 28 days (secondary outcome) for interven-
tion versus control with associated 95% confidence inter-
vals (CI). Time from randomisation to death, time from
randomisation to exclusive breastmilk feeding and length
of stay will be analysed using Kaplan–Meier plots and haz-
ard ratios, with accompanying 95% CI calculated using
Cox proportional hazards regression. All other secondary
outcomes will be analysed using appropriate regression
models accounting for the nature of the distribution of the
outcome, and results will be presented as appropriate ef-
fect sizes with a measure of precision (95% CI). Both un-
adjusted analyses and analyses adjusted for stratification
factors will be carried out. Additional exploratory analyses
will control for any baseline measures that appear to be
imbalanced between arms.
Subgroup and adjusted analyses
Subgroup analyses are planned to explore between-
group differences in the impact of KMC relative to
standard care on mortality by gestational age (< 28, 28–
32 or > 32 weeks), birthweight (< 1000, 1000–1499 or ≥
1500 g) and recruitment site. Gestational age is an im-
portant predictor of newborn survival. In settings with
newborn special care without intensive care, such as the
four trial hospitals, neonatal mortality rates are 86% in
neonates born at < 28 weeks and 41% in neonates born
at 28–31 weeks [45]. Further exploratory analyses will be
carried out to explore the association between mortality
and time of initiation (< 12, 12– < 24 or ≥ 24 h), and
continuity of KMC (median hours per day: < 6, 6– < 12,
12– < 18 or 18–24 h).
Process evaluation
The process evaluation is being conducted to strengthen
understanding of KMC initiation before stabilisation on
neonatal health outcomes, considering both intended
(beneficial) and unintended (negative) clinical effects.
Changes in neonatal care between hospitals and from
before the trial will also be assessed. This evaluation will
be conducted in accordance with the MRC guidance on
process evaluation of complex interventions [46], and
will integrate quantitative and qualitative data. Quantita-
tive outputs will include data related to causal pathways
for clinical effects, neonatal admissions data, and health
system- and facility-level survey data. Quantitative data
will be summarised using descriptive statistics. Qualita-
tive data will be collected though in-depth interviews,
focus group discussions and workshops with parents/
caregivers, healthcare providers and other key stake-
holders to identify experiences of KMC and explore fa-
cilitators and barriers to inform uptake and
sustainability. These data will be analysed using a the-
matic content approach. An iterative methodology will
be used with data collected at several time points and
then used to inform later explorations. Intervention
reporting will follow the template for intervention de-
scription and replication (TIDieR) [47], which will en-
sure a shared understanding of all activities related to
the trial intervention and, if shown to be effective,
how these relate to any proposed scale-up activities.
In addition, the TIDieR will facilitate thoughtful con-
sideration regarding the transferability of findings out-
side a trial setting and to other hospitals in Uganda
and elsewhere.
Economic evaluation
The incremental cost, cost-effectiveness, budget impact
and equity of KMC for neonates before stabilisation rela-
tive to standard care will be examined from both an ag-
gregated and a disaggregated societal perspective
(provider and household combined), in accordance with
the reference case [48]. Effects of the intervention on
neonatal health and maternal wellbeing will be assessed.
Both financial costs, which reflect actual monies paid,
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Fig. 6 CONSORT flow diagram for the OMWaNA trial
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and economic costs, which reflect the full value of re-
sources used, will be examined. Multiple data sources
will be triangulated to arrive at best estimates. Where
possible, resource use and unit costs will be collected
and presented separately, although some costs, such as
out-of-pocket payments for transport, do not permit
this. Household costs will be collected through surveys
amongst a sample of caregivers at the time of discharge
and during follow-up visits. Costs to providers will be
collected prospectively and retrospectively using project
accounts, key informant interviews, facility audits, direct
observations and time-use surveys. As necessary, sec-
ondary data on costs of treating subsequent conditions
may be supplemented with limited primary data collec-
tion in the trial hospitals. Costs and effects will be mod-
elled using a lifetime time horizon.
Discussion
Deaths in the neonatal period are responsible for 47% of
mortality in children aged < 5 years [1]. Complications
of prematurity are the leading cause, accounting for 35%
of neonatal deaths and 16% of under-5 deaths [1]. The
majority of neonatal deaths occur before stabilisation in
settings without intensive care [2]. The OMWaNA trial
will measure the impact of KMC initiated before stabil-
isation on mortality within seven days at four neonatal
units in Uganda, where intensive care is not available.
With rates of preterm birth and institutional delivery on
the rise globally [5, 6, 49], this intervention has the
potential to benefit an ever-growing number of neonates.
This trial was designed with an aim to align clinical
criteria and data definitions to facilitate future opportun-
ities for pooled analyses with related RCTs, including
the eKMC trial in The Gambia [50] and the multi-
country I-KMC trial led by WHO [37]. Several chal-
lenges were identified over the course of designing the
OMWaNA trial, the most notable of which are related
to informed consent and recruitment, non-adherence
and contextual resource limitations.
Challenge 1: timely recruitment with informed consent
Obtaining timely informed consent for this RCT may be
challenging given the involvement of sick neonates [51,
52], the fact that KMC needs to be started as soon as
possible after birth and the fact that some women may
be too ill, especially within the first 24 h, to provide con-
sent or participate. In addition, some of these women
may not be literate. Parental stress is compounded by
the fact that complications may be unexpected, espe-
cially in low-resource settings, where knowledge of
preterm birth is generally low. To help address these is-
sues, the OMWaNA trial utilises the continuous consent
approach [53], which involves providing information at
multiple time points both before and after recruitment.
Studies have found that the validity of consent improves
when discussion continues after recruitment [53]. This
approach has three main elements:
1. Parents will be given preliminary information
during neonatal eligibility screening;
2. If the neonate is eligible, a comprehensive
information sheet will be provided, and further
discussion will take place. If the parents express
willingness and ability to participate, written
informed consent will be obtained and the neonate
will be randomised;
3. During the intervention period, study staff will meet
with parents to ensure that they understand the
trial procedures and wish to continue to participate
in the trial. It will be made clear that they may
withdraw their baby from the trial at any time.
Audit data from the feasibility study at Jinja Hospital
suggest that ~ 400 eligible neonates are admitted annually
[14]. Preliminary data suggest that ~ 500 eligible neonates
each are admitted to Iganga and Entebbe Hospitals per
year and ~ 800 eligible neonates are admitted to Masaka
Hospital per year. Thus, a total population of ~ 4400 eli-
gible neonates is expected over the 24-month recruitment
period, which means a recruitment rate of ~ 50% will be
required to achieve the target sample of 2188. The feasibil-
ity study findings suggest that this is realistic and achiev-
able [14]. The trial timeline includes a three-month buffer
period in the event that recruitment is delayed or slower
than expected. Further, training of study staff emphasised
the importance of timely reporting and responsiveness to
recruitment issues.
Challenge 2: non-adherence to allocated treatment,
especially continuous KMC
Among neonates in the control group, non-adherence
with allocation (e.g. parents demanding early KMC) is a
potential issue; however, this has not been reported in
other trials [11]. Adherence in both arms, particularly the
KMC arm, could be affected by parents witnessing a death
(e.g. in the KMC position). Some babies will die regardless
of the trial arm to which they are randomised. Preterm ne-
onates can die quickly, even in settings with intensive care,
and such deaths are a recognised impediment to KMC
[54]. Stigma regarding preterm birth is common in
Uganda, but has not impeded KMC practice for stable
babies [55]. Study staff will counsel parents about the
potential for mortality at the time of enrolment as well as
counsel parents of neonates who die and those who wit-
ness a death. In addition, prompt reporting of all SAEs
and trial monitoring through regular site visits will further
facilitate timely identification of and responsiveness to any
compliance issues, should they arise.
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Adherence to the target duration of KMC (≥ 18 h/day)
may be challenging [56]. Among five RCTs that pro-
moted continuous KMC, three reported durations of ≥
20 h/day [18, 57, 58] and two did not report duration
[15, 59]. Among 16 RCTs evaluating intermittent KMC
in stable neonates, one reported mean/median duration
of 17 h/day, five reported 10–14 h/day and nine reported
< 10 h/day [60]. The OMWaNA trial will employ a
comprehensive approach to improve adherence. An il-
lustrated KMC handout will be provided to caregivers at
the time of enrolment. Study staff will counsel mothers
about the benefits of KMC throughout the hospital stay,
including the time of discharge. Studies have noted the
importance of staff training and counselling for KMC
[61, 62], and a related RCT demonstrated the efficacy of
peer-counselling in promoting breastfeeding among hos-
pitalised preterm neonates [63]. We will establish KMC
peer-counselling programmes at each site, enlisting
mothers who practiced KMC as participants when they
return for follow-up. Peer counselling will address many
maternal concerns and may help facilitate longer dura-
tions of KMC. We will also engage hospital administra-
tors about KMC guidelines. Adjustable beds and KMC
wraps will be provided, as these have been shown to
improve adherence [56]. Lack of privacy and inadequate
space for beds and equipment were identified as signifi-
cant barriers to KMC practice in the feasibility study [14].
Provision of increased space within the four neonatal units
may facilitate caregiver privacy as well as help improve
clinical providers’ ability to safely care for at-risk neonates.
Despite these measures, this is a pragmatic trial and some
non-adherence is inevitable. The effect of non-adherence
might be to dilute the size of the effect of KMC (assuming
it ‘works’) and this has been factored into the sample size
calculations. Biannual neonatal quality of care surveys,
including progress monitoring of KMC provision/services,
will be conducted at the four sites as part of the process
evaluation.
Challenge 3: context including infrastructure, supplies
and equipment
Over the six months preceding the start of the trial, the
study team has made extensive efforts to expand neonatal
care capacity at the four hospitals. Improvements include
increased space and water supply in the neonatal units,
office space for clinical staff, bathrooms/toilets for care-
givers, adjustable beds for KMC, and various equipment
and supplies. Despite these efforts, context-related re-
source constraints are inevitable. In government facilities,
such as the four trial hospitals, supply/medication short-
ages are common and repair of malfunctioning equipment
(e.g. incubators, oxygen concentrators) is often protracted.
Triannual (every four months) surveys of staffing,
equipment, supply and medication availability, and
infrastructure across the sites are included in the process
evaluation. In addition to the supplies and equipment pro-
vided before trial commencement, the budget includes a
small allowance to help cover the cost of necessary com-
modities for each participating neonate.
Electrical power is required for incubators, radiant
warmers, oxygen concentrators and phototherapy. Lack
of access to reliable electricity is a problem in many
LMICs, including Uganda, where a 2007 national survey
showed that only 19% of government hospitals had
reliable electricity (during working hours) or a backup
generator with fuel [64]. In 2014, a study at Jinja
Hospital recorded 120 episodes of power failure (mean
of 13 times/week), with a median duration of 30 min
each, over a 64-day period [65]. The four trial hospitals
have reliable power supply, with occasional brief power
outages (e.g. when back-up generators run out of fuel).
Daily communication between staff at the MRC/UVRI
and LSHTM Unit and the sites will facilitate timely iden-
tification and resolution of any significant power outages
impacting patient care. Frequency and duration of power
outages will be recorded by site staff.
Conclusion
The OMWaNA trial will assess the effectiveness of
KMC in reducing mortality among neonates before sta-
bilisation, a population where the benefits of KMC are
currently uncertain. These findings are expected to have
broad applicability to hospitals in low-resource settings
and important policy and programme implications. The
trial will be among the first to rigorously compare the
incremental cost and cost-effectiveness of KMC and
standard care, taking into account family members’ time,
which will be crucial to ensure the sustainability of this
intervention. Additionally, OMWaNA will advance un-
derstanding of the underlying mechanisms for the effects
of KMC before stabilisation, including prematurity-
associated brain injury, which could help inform preven-
tion of disability as well as guide further innovation to
improve survival for preterm newborns in the highest
mortality settings.
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